The EBNA3 family: Two oncoproteins and a tumour suppressor that are central to the biology of EBV in B cells

Current Topics in Microbiology and Immunology

Volumn 391, Issue , 2015, Pages 61-117

  Allday, Martin J ^a   Bazot, Quentin ^a   White, Robert E ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; C PROMOTER BINDING FACTOR 1; C TERMINAL BINDING PROTEIN 1; C TERMINAL BINDING PROTEIN 2; CXCL9 CHEMOKINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 3A; EPSTEIN BARR VIRUS ANTIGEN 3B; EPSTEIN BARR VIRUS ANTIGEN 3C; EPSTEIN BARR VIRUS ANTIGEN A1; EPSTEIN BARR VIRUS ANTIGEN A2; EPSTEIN BARR VIRUS ANTIGEN LP; GAMMA INTERFERON INDUCIBLE PROTEIN 10; ONCOPROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; EBNA-3A ANTIGEN; EBNA-3B ANTIGEN; EBNA-3C, EPSTEIN-BARR VIRUS; TUMOR SUPPRESSOR PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADAM28 GENE; ADAMDEC1 GENE; AMINO TERMINAL SEQUENCE; B LYMPHOCYTE; BCL2L11 GENE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CXCL10 GENE; CXCL11 GENE; CXCL9 GENE; DNA BINDING; DROSOPHILA MELANOGASTER; EBNA3A GENE; EBNA3B GENE; EBNA3C GENE; EPIGENETICS; EPSTEIN BARR VIRUS; EXON; FIBROBLAST; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE CLUSTER; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCRYPTOVIRUS; LYMPHOMAGENESIS; MICROARRAY ANALYSIS; NONHUMAN; NUCLEAR REPROGRAMMING; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS LATENCY; ANIMAL; EPSTEIN BARR VIRUS INFECTION; GENETICS; METABOLISM; MULTIGENE FAMILY; VIROLOGY;

ANIMALS; B-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; MULTIGENE FAMILY; ONCOGENE PROTEINS, VIRAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84943229944     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/978-3-319-22834-1_3     Document Type: Chapter

References (204)

1. Acosta JC, Gil J (2012) Senescence: a new weapon for cancer therapy. Trends Cell Biol 22:211-219
2. Allday MJ (2013) EBV finds a polycomb-mediated, epigenetic solution to the problem of oncogenic stress responses triggered by infection. Front Genet 4:212
3. Allday MJ, Crawford DH, Griffin BE (1988) Prediction and demonstration of a novel Epstein-Barr virus nuclear antigen. Nucleic Acids Res 16:4353-4367
4. Allday MJ, Crawford DH, Griffin BE (1989) Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J Gen Virol 70(Pt 7):1755-1764
5. Allday MJ, Farrell PJ (1994) Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol 68:3491-3498
6. Altmann M, Hammerschmidt W (2005) Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 3:e404
7. Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27:421-433
8. Arvey A, Tempera I, Tsai K, Chen HS, Tikhmyanova N, Klichinsky M, Leslie C, Lieberman PM (2012) An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe 12:233-245
9. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA (1999) Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 190:567-576
10. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA (1998) EBV persistence in memory B cells in vivo. Immunity 9:395-404
11. Babcock GJ, Hochberg D, Thorley-Lawson AD (2000) The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13:497-506
12. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C et al (1984) DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310:207-211
13. Bain M, Watson RJ, Farrell PJ, Allday MJ (1996) Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J Virol 70:2481-2489
14. Bajaj BG, Murakami M, Cai Q, Verma SC, Lan K, Robertson ES (2008) Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol 82:4082-4090
15. Banerjee S, Lu J, Cai Q, Saha A, Jha HC, Dzeng RK, Robertson ES (2013) The EBV latent antigen 3C inhibits apoptosis through targeted regulation of interferon regulatory factors 4 and 8. PLoS Pathog 9:e1003314
16. Barolo S, Stone T, Bang AG, Posakony JW (2002) Default repression and Notch signaling: hairless acts as an adaptor to recruit the corepressors Groucho and dCtBP to suppressor of hairless. Genes Dev 16:1964-1976
17. Bartek J, Bartkova J, Lukas J (2007) DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26:7773-7779
18. Bazot Q, Deschamps T, Tafforeau L, Siouda M, Leblanc P, Harth-Hertle ML, Rabourdin-Combe C, Lotteau V, Kempkes B, Tommasino M, Gruffat H, Manet E (2014) Epstein-Barr virus nuclear antigen 3A protein regulates CDKN2B transcription via interaction with MIZ-1. Nucleic Acids Res 42:9700-9716
19. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315-326
20. Bickmore WA (2013) The spatial organization of the human genome. Annu Rev Genomics Hum Genet 14:67-84
21. Bickmore WA, van Steensel B (2013) Genome architecture: domain organization of interphase chromosomes. Cell 152:1270-1284
22. Bourillot PY, Waltzer L, Sergeant A, Manet E (1998) Transcriptional repression by the Epstein-Barr virus EBNA3A protein tethered to DNA does not require RBP-Jkappa. J Gen Virol 79(Pt 2):363-370
23. Braig M, Schmitt CA (2006) Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res 66:2881-2884
24. Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M, James MC, Vatcheva R, Bates S, Vousden KH, Parry D, Gruis N, Smit N, Bergman W, Peters G (2002) INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 21:2936-2945
25. Brown AC, Baigent SJ, Smith LP, Chattoo JP, Petherbridge LJ, Hawes P, Allday MJ, Nair V (2006) Interaction of MEQ protein and C-terminal-binding protein is critical for induction of lymphomas by Marek's disease virus. Proc Natl Acad Sci USA 103:1687-1692
26. Buck M, Burgess A, Stirzaker R, Krauer K, Sculley T (2006) Epstein-Barr virus nuclear antigen 3A contains six nuclear-localization signals. J Gen Virol 87:2879-2884
27. Burgess A, Buck M, Krauer K, Sculley T (2006) Nuclear localization of the Epstein-Barr virus EBNA3B protein. J Gen Virol 87:789-793
28. Cai Q, Guo Y, Xiao B, Banerjee S, Saha A, Lu J, Glisovic T, Robertson ES (2011) Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog 7:e1002418
29. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, Raab-Traub N, Cullen BR (2006) Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2:e23
30. Calderwood MA, Lee S, Holthaus AM, Blacklow SC, Kieff E, Johannsen E (2011) Epstein-Barr virus nuclear protein 3C binds to the N-terminal (NTD) and beta trefoil domains (BTD) of RBP/CSL; only the NTD interaction is essential for lymphoblastoid cell growth. Virology 414:19-25
31. Calderwood MA, Venkatesan K, Xing L, Chase MR, Vazquez A, Holthaus AM, Ewence AE, Li N, Hirozane-Kishikawa T, Hill DE, Vidal M, Kieff, Johannsen E (2007) Epstein-Barr virus and virus human protein interaction maps. Proc Natl Acad Sci USA 104:7606-7611
32. Campos EI, Stafford JM, Reinberg D (2014) Epigenetic inheritance: histone bookmarks across generations. Trends Cell Biol 24:664-674
33. Cedar H, Bergman Y (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10:295-304
34. Chen A, Divisconte M, Jiang X, Quink C, Wang F (2005) Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro. J Virol 79:4506-4509
35. Chen A, Zhao B, Kieff E, Aster JC, Wang F (2006) EBNA-3B-and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol 80:10139-10150
36. Chinnadurai G (2007) Transcriptional regulation by C-terminal binding proteins. Int J Biochem Cell Biol 39:1593-1607
37. Choudhuri T, Verma SC, Lan K, Murakami M, Robertson ES (2007) The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J Virol 81:6718-6730
38. Choudhuri T, Verma SC, Lan K, Robertson ES (2006) Expression of alpha V integrin is modulated by Epstein-Barr virus nuclear antigen 3C and the metastasis suppressor Nm23-H1 through interaction with the GATA-1 and Sp1 transcription factors. Virology 351:58-72
39. Cludts I, Farrell PJ (1998) Multiple functions within the Epstein-Barr virus EBNA-3A protein. J Virol 72:1862-1869
40. Cooper A, Johannsen E, Maruo S, Cahir-McFarland E, Illanes D, Davidson D, Kieff E (2003) EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth. J Virol 77:999-1010
41. Cotter MA 2nd, Robertson ES (2000) Modulation of histone acetyltransferase activity through interaction of epstein-barr nuclear antigen 3C with prothymosin alpha. Mol Cell Biol 20:5722-5735
42. Crawford DH (2001) Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 356:461-473
43. Dalbies-Tran R, Stigger-Rosser E, Dotson T, Sample CE (2001) Amino acids of Epstein-Barr virus nuclear antigen 3A essential for repression of Jkappa-mediated transcription and their evolutionary conservation. J Virol 75:90-99
44. Dang CV, O'Donnell KA, Juopperi T (2005) The great MYC escape in tumorigenesis. Cancer Cell 8:177-178
45. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS (1993) Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 177:339-349
46. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W (1998) Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci USA 95:8245-8250
47. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD (2002) IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168:3195-3204
48. Egle A, Harris AW, Bouillet P, Cory S (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 101:6164-6169
49. Ehlers B, Ochs A, Leendertz F, Goltz M, Boesch C, Matz-Rensing K (2003) Novel simian homologues of Epstein-Barr virus. J Virol 77:10695-10699
50. Ehlers B, Spiess K, Leendertz F, Peeters M, Boesch C, Gatherer D, McGeoch DJ (2010) Lymphocryptovirus phylogeny and the origins of Epstein-Barr virus. J Gen Virol 91:630-642
51. Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, Rosenstengel A, Nguyen T, Allworth A, Burrows SR, Cox J, Pye D, Moss DJ, Bharadwaj M (2008) Phase I trial of a CD8+T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 82:1448-1457
52. Epstein MA (2001) Historical background. Philos Trans R Soc Lond B Biol Sci 356:413-420
53. Feederle R, Bartlett EJ, Delecluse HJ (2010) Epstein-Barr virus genetics: talking about the BAC generation. Herpesviridae 1:6
54. Fischer SF, Bouillet P, O'Donnell K, Light A, Tarlinton DM, Strasser A (2007) Proapoptotic BH3-only protein Bim is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells. Blood 110:3978-3984
55. Garrido JL, Maruo S, Takada K, Rosendorff A (2009) EBNA3C interacts with Gadd34 and counteracts the unfolded protein response. Virol J 6:231
56. Gil J, Peters G (2006) Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 7:667-677
57. Gorzer I, Niesters HG, Cornelissen JJ, Puchhammer-Stockl E (2006) Characterization of Epstein-Barr virus Type I variants based on linked polymorphism among EBNA3A,-3B, and-3C genes. Virus Res 118:105-114
58. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM (2001) An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97:835-843
59. Gruhne B, Sompallae R, Masucci MG (2009) Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene 28:3997-4008
60. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S (2012) The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet 13:654-666
61. Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. Science 319:1352-1355
62. Harth-Hertle ML, Scholz BA, Erhard F, Glaser LV, Dolken L, Zimmer R, Kempkes B (2013) Inactivation of intergenic enhancers by EBNA3A initiates and maintains polycomb signatures across a chromatin domain encoding CXCL10 and CXCL9. PLoS Pathog 9:e1003638
63. Hawkins JB, Delgado-Eckert E, Thorley-Lawson DA, Shapiro M (2013) The cycle of EBV infection explains persistence, the sizes of the infected cell populations and which come under CTL regulation. PLoS Pathog 9:e1003685
64. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW (2005) Evasion of the p53 tumour surveillance network by tumourderived MYC mutants. Nature 436:807-811
65. Hennessy K, Fennewald S, Kieff E (1985) A third viral nuclear protein in lymphoblasts immortalized by Epstein-Barr virus. Proc Natl Acad Sci USA 82:5944-5948
66. Hennessy K, Wang F, Bushman EW, Kieff E (1986) Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family. Proc Natl Acad Sci USA 83:5693-5697
67. Hertle ML, Popp C, Petermann S, Maier S, Kremmer E, Lang R, Mages J, Kempkes B (2009) Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog 5:e1000506
68. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925-935
69. Hickabottom M, Parker GA, Freemont P, Crook T, Allday MJ (2002) Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxylterminal-binding protein (CtBP). J Biol Chem 277:47197-47204
70. Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25:587-617
71. Humeniuk R, Rosu-Myles M, Fares J, Koller R, Bies J, Wolff L (2013) The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate. Blood Cancer J 3:e99
72. Isaksson A, Berggren M, Ricksten A (2003) Epstein-Barr virus U leader exon contains an internal ribosome entry site. Oncogene 22:572-581
73. Jha HC, Aj MP, Saha A, Banerjee S, Lu J, Robertson ES (2014) Epstein-Barr virus essential antigen EBNA3C attenuates H2AX expression. J Virol 88:3776-3788
74. Jha HC, Lu J, Saha A, Cai Q, Banerjee S, Prasad MA, Robertson ES (2013) EBNA3C-mediated regulation of aurora kinase B contributes to Epstein-Barr virus-induced B-cell proliferation through modulation of the activities of the retinoblastoma protein and apoptotic caspases. J Virol 87:12121-12138
75. Jiang H, Cho YG, Wang F (2000) Structural, functional, and genetic comparisons of Epstein-Barr virus nuclear antigen 3A, 3B, and 3C homologues encoded by the rhesus lymphocryptovirus. J Virol 74:5921-5932
76. Jiang S, Willox B, Zhou H, Holthaus AM, Wang A, Shi TT, Maruo S, Kharchenko PV, Johannsen EC, Kieff E, Zhao B (2014) Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A. Proc Natl Acad Sci USA 111:421-426
77. Jimenez-Ramirez C, Brooks AJ, Forshell LP, Yakimchuk K, Zhao B, Fulgham TZ, Sample CE (2006) Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter. J Virol 80:11200-11208
78. Johannsen E, Miller CL, Grossman SR, Kieff E (1996) EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes. J Virol 70:4179-4183
79. Joseph AM, Babcock GJ, Thorley-Lawson DA (2000) Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 74:9964-9971
80. Kashuba E, Yurchenko M, Yenamandra SP, Snopok B, Isaguliants M, Szekely L, Klein G (2008) EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes. Proc Natl Acad Sci USA 105:5489-5494
81. Kaul R, Verma SC, Murakami M, Lan K, Choudhuri T, Robertson ES (2006) Epstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1. J Virol 80:1321-1331
82. Kelly G, Bell A, Rickinson A (2002) Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 8:1098-1104
83. Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, Bell AI, Bornkamm GW, Mautner J, Rickinson AB, Rowe M (2009) An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog 5:e1000341
84. Kelly GL, Stylianou J, Rasaiyaah J, Wei W, Thomas W, Croom-Carter D, Kohler C, Spang R, Woodman C, Kellam P, Rickinson AB, Bell AI (2013) Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BLassociated gene expression signature. J Virol 87:2882-2894
85. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ (1992) Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 176:169-176
86. Khanna R, Slade RW, Poulsen L, Moss DJ, Burrows SR, Nicholls J, Burrows JM (1997) Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J Virol 71:8340-8346
87. Kheradmand Kia S, Solaimani Kartalaei P, Farahbakhshian E, Pourfarzad F, von Lindern M, Verrijzer CP (2009) EZH2-dependent chromatin looping controls INK4a and INK4b, but not ARF, during human progenitor cell differentiation and cellular senescence. Epigenetics Chromatin 2:16
88. Kienzle N, Young DB, Liaskou D, Buck M, Greco S, Sculley TB (1999) Intron retention may regulate expression of Epstein-Barr virus nuclear antigen 3 family genes. J Virol 73:1195-1204
89. Kim SM, Kang SH, Lee WK (2006) Identification of two types of naturally-occurring intertypic recombinants of Epstein-Barr virus. Mol Cells 21:302-307
90. Kis LL, Takahara M, Nagy N, Klein G, Klein E (2006) Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. Immunol Lett 104:83-88
91. Kis LL, Salamon D, Persson EK, Nagy N, Scheeren FA, Spits H, Klein G, Klein E (2010) IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of Cand activation of LMP-1-promoter. Proc Natl Acad Sci USA 107:872-877
92. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG (1998) p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 91:1680-1687
93. Knight JS, Lan K, Subramanian C, Robertson ES (2003) Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 77:4261-4272
94. Knight JS, Robertson ES (2004) Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. J Virol 78:1981-1991
95. Knight JS, Sharma N, Kalman DE, Robertson ES (2004) A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J Virol 78:12857-12867
96. Knight JS, Sharma N, Robertson ES (2005a) Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci USA 102:18562-18566
97. Knight JS, Sharma N, Robertson ES (2005b) SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol 25:1749-1763
98. Kohlhof H, Hampel F, Hoffmann R, Burtscher H, Weidle UH, Holzel M, Eick D, Zimber-Strobl U, Strobl LJ (2009) Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells. Blood 113:5506-5515
99. Krauer K, Buck M, Flanagan J, Belzer D, Sculley T (2004a) Identification of the nuclear localization signals within the Epstein-Barr virus EBNA-6 protein. J Gen Virol 85:165-172
100. Krauer KG, Buck M, Belzer DK, Flanagan J, Chojnowski GM, Sculley TB (2004b) The Epstein-Barr virus nuclear antigen-6 protein co-localizes with EBNA-3 and survival of motor neurons protein. Virology 318:280-294
101. LeRoux A, Berebbi M, Moukaddem M, Perricaudet M, Joab I (1993) Identification of a short amino acid sequence essential for efficient nuclear targeting of the Epstein-Barr virus nuclear antigen 3A. J Virol 67:1716-1720
102. LeRoux A, Kerdiles B, Walls D, Dedieu JF, Perricaudet M (1994) The Epstein-Barr virus determined nuclear antigens EBNA-3A,-3B, and-3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology 205:596-602
103. Lee S, Sakakibara S, Maruo S, Zhao B, Calderwood MA, Holthaus AM, Lai CY, Takada K, Kieff E, Johannsen E (2009) Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1. J Virol 83:12368-12377
104. Lin J, Johannsen E, Robertson E, Kieff E (2002) Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J Virol 76:232-242
105. Lowe SW, Cepero E, Evan G (2004) Intrinsic tumour suppression. Nature 432:307-315
106. Maruo S, Johannsen E, Illanes D, Cooper A, Kieff E (2003) Epstein-Barr virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth. J Virol 77:10437-10447
107. Maruo S, Johannsen E, Illanes D, Cooper A, Zhao B, Kieff E (2005) Epstein-Barr virus nuclear protein 3A domains essential for growth of lymphoblasts: transcriptional regulation through RBP-Jkappa/CBF1 is critical. J Virol 79:10171-10179
108. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, Takada K (2006) Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci USA 103:19500-19505
109. Maruo S, Wu Y, Ito T, Kanda T, Kieff ED, Takada K (2009) Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth. Proc Natl Acad Sci USA 106:4419-4424
110. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K (2011) Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci USA 108:1919-1924
111. McAulay KA, Haque T, Urquhart G, Bellamy C, Guiretti D, Crawford DH (2009) Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease. J Immunol 182:3892-3901
112. McClellan MJ, Khasnis S, Wood CD, Palermo RD, Schlick SN, Kanhere AS, Jenner RG, West MJ (2012) Downregulation of integrin receptor-signaling genes by Epstein-Barr virus EBNA 3C via promoter-proximal and-distal binding elements. J Virol 86:5165-5178
113. McClellan MJ, Wood CD, Ojeniyi O, Cooper TJ, Kanhere A, Arvey A, Webb HM, Palermo RD, Harth-Hertle ML, Kempkes B, Jenner RG, West MJ (2013) Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming. PLoS Pathog 9:e1003636
114. Midgley RS, Bell AI, McGeoch DJ, Rickinson AB (2003) Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes. J Virol 77:11517-11530
115. Midgley RS, Blake NW, Yao QY, Croom-Carter D, Cheung ST, Leung SF, Chan AT, Johnson PJ, Huang D, Rickinson AB, Lee SP (2000) Novel intertypic recombinants of epstein-barr virus in the chinese population. J Virol 74:1544-1548
116. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, Pages F, Trajanoski Z, Galon J (2010) Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138:1429-1440
117. Morel V, Lecourtois M, Massiani O, Maier D, Preiss A, Schweisguth F (2001) Transcriptional repression by suppressor of hairless involves the binding of a hairless-dCtBP complex in Drosophila. Curr Biol 11:789-792
118. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB (1992) Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 176:157-168
119. Nagy E, Veress G, Szarka K, Csoma E, Beck Z (2005) Frequent methylation of p16INK4A/ p14ARF promoters in tumorigenesis of Epstein-Barr virus transformed lymphoblastoid cell lines. Anticancer Res 25:2153-2160
120. Nagy N, Adori M, Rasul A, Heuts F, Salamon D, Ujvari D, Madapura HS, Leveau B, Klein G, Klein E (2012) Soluble factors produced by activated CD4+T cells modulate EBV latency. Proc Natl Acad Sci USA 109:1512-1517
121. Naumova N, Smith EM, Zhan Y, Dekker J (2012) Analysis of long-range chromatin interactions using chromosome conformation capture. Methods 58:192-203
122. Nguyen-Van D, Keane C, Han E, Jones K, Nourse JP, Vari F, Ross N, Crooks P, Ramuz O, Green M, Griffith L, Trappe R, Grigg A, Mollee P, Gandhi MK (2011) Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. Am J Blood Res 1:146-159
123. Nikiforow S, Lacasce AS (2014) Targeting Epstein-Barr virus-associated lymphomas. J Clin Oncol 32:830-832
124. Nikitin PA, Luftig MA (2012) The DNA damage response in viral-induced cellular transformation. Br J Cancer 106:429-435
125. Nikitin PA, Yan CM, Forte E, Bocedi A, Tourigny JP, White RE, Allday MJ, Patel A, Dave SS, Kim W, Hu K, Guo J, Tainter D, Rusyn E, Luftig MA (2010) An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe 8:510-522
126. O'Nions J, Turner A, Craig R, Allday MJ (2006) Epstein-Barr virus selectively deregulates DNA damage responses in normal B cells but has no detectable effect on regulation of the tumor suppressor p53. J Virol 80:12408-12413
127. Palmero I, Holder A, Sinclair AJ, Dickson C, Peters G (1993) Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines. Oncogene 8:1049-1054
128. Parker GA, Crook T, Bain M, Sara EA, Farrell PJ, Allday MJ (1996) Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13:2541-2549
129. Parker GA, Touitou R, Allday MJ (2000) Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene 19:700-709
130. Paschos K, Parker GA, Watanatanasup E, White RE, Allday MJ (2012) BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res 40:7233-7246
131. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ (2009) Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5:e1000492
132. Peng R, Moses SC, Tan J, Kremmer E, Ling PD (2005) The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter. J Virol 79:4492-4505
133. Petti L, Kieff E (1988) A sixth Epstein-Barr virus nuclear protein (EBNA3B) is expressed in latently infected growth-transformed lymphocytes. J Virol 62:2173-2178
134. Petti L, Sample C, Kieff E (1990) Subnuclear localization and phosphorylation of Epstein-Barr virus latent infection nuclear proteins. Virology 176:563-574
135. Petti L, Sample J, Wang F, Kieff E (1988) A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J Virol 62:1330-1338
136. Pokrovskaja K, Ehlin-Henriksson B, Bartkova J, Bartek J, Scuderi R, Szekely L, Wiman KG, Klein G (1996) Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines. Cell Growth Differ 7:1723-1732
137. Price AM, Tourigny JP, Forte E, Salinas RE, Dave SS, Luftig MA (2012) Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-kappaB activation. J Virol 86:11096-11106
138. Radkov SA, Bain M, Farrell PJ, West M, Rowe M, Allday MJ (1997) Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol 71:8552-8562
139. Radkov SA, Touitou R, Brehm A, Rowe M, West M, Kouzarides T, Allday MJ (1999) Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 73:5688-5697
140. Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, Calasanz MJ, Panizo C, Richter JA, Hernandez JM, Roman-Gomez J, Prosper F, Martinez-Climent JA (2010) Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 116:2531-2542
141. Ricksten A, Kallin B, Alexander H, Dillner J, Fahraeus R, Klein G, Lerner R, Rymo L (1988) BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci USA 85:995-999
142. Rivailler P, Cho YG, Wang F (2002) Complete genomic sequence of an Epstein-Barr virusrelated herpesvirus naturally infecting a new world primate: a defining point in the evolution of oncogenic lymphocryptoviruses. J Virol 76:12055-12068
143. Robertson ES, Grossman S, Johannsen E, Miller C, Lin J, Tomkinson B, Kieff E (1995) Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol 69:3108-3116
144. Robertson ES, Lin J, Kieff E (1996) The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol 70:3068-3074
145. Rochford R, Hobbs MV, Garnier JL, Cooper NR, Cannon MJ (1993) Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc Natl Acad Sci USA 90:352-356
146. Rosendorff A, Illanes D, David G, Lin J, Kieff E, Johannsen E (2004) EBNA3C coactivation with EBNA2 requires a SUMO homology domain. J Virol 78:367-377
147. Roughan JE, Thorley-Lawson DA (2009) The intersection of Epstein-Barr virus with the germinal center. J Virol 83:3968-3976
148. Saha A, Bamidele A, Murakami M, Robertson ES (2011) EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol 85:2079-2088
149. Saha A, Lu J, Morizur L, Upadhyay SK, Aj MP, Robertson ES (2012) E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog 8:e1002573
150. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES (2009) Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 83:4652-4669
151. Salamon D, Adori M, Ujvari D, Wu L, Kis LL, Madapura HS, Nagy N, Klein G, Klein E (2012) Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells. J Virol 86:4701-4707
152. Sample C, Parker B (1994) Biochemical characterization of Epstein-Barr virus nuclear antigen 3A and 3C proteins. Virology 205:534-539
153. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A (1990) Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 64:4084-4092
154. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602
155. Sewalt RG, Gunster MJ, van der Vlag J, Satijn DP, Otte AP (1999) C-Terminal binding protein is a transcriptional repressor that interacts with a specific class of vertebrate Polycomb proteins. Mol Cell Biol 19:777-787
156. Shannon-Lowe C, Baldwin G, Feederle R, Bell A, Rickinson A, Delecluse HJ (2005) Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth. J Gen Virol 86:3009-3019
157. Sherr CJ (2012) Ink4-arf locus in cancer and aging. Wiley Interdiscip Rev Dev Biol 1:731-741
158. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941-953
159. Shi Y, Sawada J, Sui G, el Affar B, Whetstine JR, Lan F, Ogawa H, Luke MP, Nakatani Y, Shi Y (2003) Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422:735-738
160. Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Kuppers R (2008) EBV transformation overrides gene expression patterns of B cell differentiation stages. Mol Immunol 45:3133-3141
161. Sinclair AJ, Palmero I, Peters G, Farrell PJ (1994) EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 13:3321-3328
162. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ (2010) Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6:e1000951
163. Skalska L, White RE, Parker GA, Sinclair AJ, Paschos K, Allday MJ (2013) Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog 9:e1003187
164. Spender LC, Cannell EJ, Hollyoake M, Wensing B, Gawn JM, Brimmell M, Packham G, Farrell PJ (1999) Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J Virol 73:4678-4688
165. Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB (1996) Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med 184:1801-1813
166. Stock JK, Giadrossi S, Casanova M, Brookes E, Vidal M, Koseki H, Brockdorff N, Fisher AG, Pombo A (2007) Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells. Nat Cell Biol 9:1428-1435
167. Strasser A (2005) The role of BH3-only proteins in the immune system. Nat Rev Immunol 5:189-200
168. Strowig T, Gurer C, Ploss A, Liu YF, Arrey F, Sashihara J, Koo G, Rice CM, Young JW, Chadburn A, Cohen JI, Munz C (2009) Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 206:1423-1434
169. Subramanian C, Cotter MA 2nd, Robertson ES (2001) Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: a molecular link to cancer metastasis. Nat Med 7:350-355
170. Sundqvist A, Sollerbrant K, Svensson C (1998) The carboxy-terminal region of adenovirus E1A activates transcription through targeting of a C-terminal binding protein-histone deacetylase complex. FEBS Lett 429:183-188
171. Tempera I, Lieberman PM (2014) Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol 26:22-29
172. Thorley-Lawson DA, Allday MJ (2008) The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 6:913-924
173. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350:1328-1337
174. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M (2013) The pathogenesis of Epstein-Barr virus persistent infection. Curr Opin Virol
175. Thorley-Lawson DA, Strominger JL (1978) Reversible inhibition by phosphonoacetic acid of human B lymphocyte transformation by Epstein-Barr virus. Virology 86:423-431
176. Tomkinson B, Kieff E (1992a) Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection. J Virol 66:780-789
177. Tomkinson B, Kieff E (1992b) Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol 66:2893-2903
178. Tomkinson B, Robertson E, Kieff E (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 67:2014-2025
179. Touitou R, Arbach H, Cochet C, Feuillard J, Martin A, Raphael M, Joab I (2003) Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines. J Gen Virol 84:949-957
180. Touitou R, Hickabottom M, Parker G, Crook T, Allday MJ (2001) Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J Virol 75:7749-7755
181. Touitou R, O'Nions J, Heaney J, Allday MJ (2005) Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells. J Gen Virol 86:1269-1277
182. Vereide DT, Sugden B (2011) Lymphomas differ in their dependence on Epstein-Barr virus. Blood 117:1977-1985
183. Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137:413-431
184. Waltzer L, Perricaudet M, Sergeant A, Manet E (1996) Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA. J Virol 70:5909-5915
185. Watanabe A, Maruo S, Ito T, Ito M, Katsumura KR, Takada K (2010) Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1. J Virol 84:2893-2901
186. West MJ (2006) Structure and function of the Epstein-Barr virus transcription factor, EBNA 3C. Curr Protein Pept Sci 7:123-136
187. West MJ, Webb HM, Sinclair AJ, Woolfson DN (2004) Biophysical and mutational analysis of the putative bZIP domain of Epstein-Barr virus EBNA 3C. J Virol 78:9431-9445
188. White RE, Groves IJ, Turro E, Yee J, Kremmer E, Allday MJ (2010) Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS ONE 5:e13979
189. White RE, Ramer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, Savoldo B, Coutinho R, Bodor C, Gribben J, Ibrahim HA, Bower M, Nourse JP, Gandhi MK, Middeldorp J, Cader FZ, Murray P, Munz C, Allday MJ (2012) EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 122:1487-1502
190. Yao QY, Rowe M, Martin B, Young LS, Rickinson AB (1991) The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers. J Gen Virol 72(Pt 7):1579-1590
191. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, Gil J, Walsh MJ, Zhou MM (2010) Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38:662-674
192. Yee J, White RE, Anderton E, Allday MJ (2011) Latent Epstein-Barr virus can inhibit apoptosis in B cells by blocking the induction of NOXA expression. PLoS ONE 6:e28506
193. Yenamandra SP, Sompallae R, Klein G, Kashuba E (2009) Comparative analysis of the Epstein-Barr virus encoded nuclear proteins of EBNA-3 family. Comput Biol Med 39:1036-1042
194. Yi F, Saha A, Murakami M, Kumar P, Knight JS, Cai Q, Choudhuri T, Robertson ES (2009) Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388:236-247
195. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB (1988) Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69(Pt 5):1051-1065
196. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4:757-768
197. Young LS, Yao QY, Rooney CM, Sculley TB, Moss DJ, Rupani H, Laux G, Bornkamm GW, Rickinson AB (1987) New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol 68(Pt 11):2853-2862
198. Young P, Anderton E, Paschos K, White R, Allday MJ (2008) Epstein-Barr virus nuclear antigen (EBNA) 3A induces the expression of and interacts with a subset of chaperones and cochaperones. J Gen Virol 89:866-877
199. Zhang Q, Wang SY, Nottke AC, Rocheleau JV, Piston DW, Goodman RH (2006) Redox sensor CtBP mediates hypoxia-induced tumor cell migration. Proc Natl Acad Sci USA 103:9029-9033
200. Zhao B, Dalbies-Tran R, Jiang H, Ruf IK, Sample JT, Wang F, Sample CE (2003) Transcriptional regulatory properties of Epstein-Barr virus nuclear antigen 3C are conserved in simian lymphocryptoviruses. J Virol 77:5639-5648
201. Zhao B, Mar JC, Maruo S, Lee S, Gewurz BE, Johannsen E, Holton K, Rubio R, Takada K, Quackenbush J, Kieff E (2011) Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci USA 108:337-342
202. Zhao B, Sample CE (2000) Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site. J Virol 74:5151-5160
203. Zhao LJ, Subramanian T, Vijayalingam S, Chinnadurai G (2014) CtBP2 proteome: role of CtBP in E2F7-mediated repression and cell proliferation. Genes Cancer 5:31-40
204. Zimber-Strobl U, Strobl LJ (2001) EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin Cancer Biol 11:423-434